Precision BioSciences announced that it has received Clinical Trial Application approval to expand its global ELIMINATE‑B trial of PBGENE‑HBV into France and Romania. The approval allows the company to open new trial sites in these European countries, broadening patient enrollment for its first‑in‑human gene‑editing program targeting hepatitis B.
ELIMINATE‑B is a Phase 1, open‑label, first‑in‑human dose‑escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, and antiviral activity of PBGENE‑HBV. The trial currently includes sites in the United Kingdom, Moldova, New Zealand, Hong Kong, and the United States, and the new French and Romanian sites are expected to begin patient screening in Q2 2026.
Expanding into France and Romania increases the geographic diversity of the study and accelerates the pace at which the company can collect safety and efficacy data needed for future regulatory submissions. The move also strengthens the evidence base for the ARCUS platform and supports Precision’s strategy of demonstrating clinical utility in high‑unmet‑need indications, positioning the company for its 2026 clinical milestones.
Precision’s financial position provides a solid foundation for the expansion. As of December 31 2025, the company held approximately $137.2 million in cash, cash equivalents, and restricted cash, giving it a runway through 2028. The liquidity cushion supports continued investment in the ELIMINATE‑B program and other pipeline assets.
Cindy Atwell, Chief Development and Business Officer, said, “Expanding ELIMINATE‑B into hepatitis sites in France and Romania is an important step in the continued development of PBGENE‑HBV, the only gene‑editing therapy uniquely designed to eliminate cccDNA.” She added that strong investigator interest followed a presentation at The Liver Conference 2025.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.